Lorena Incorvaia - Concepedia

Author

Lorena Incorvaia

University of Palermo ORCID

Also Known As

Debora Ierinò, Incorvaia, Lorena, L Galli, L Incorvaia, L. Incorvaia, Lorena INCORVAIA, Lorena Incorvaia, Stefania Gori

247

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

University of Palermo Istituti di Ricovero e Cura a Carattere Scientifico Fondazione IRCCS Istituto Nazionale dei Tumori Istituto Oncologico Veneto European Institute of Oncology

About

Lorena Incorvaia is an author at University of Palermo specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	708
2	Engineering	1	1	14
3	Health Sciences	1	1	31
4	Public Health	1	1	16
5	Allergy	1	1	40

Lorena Incorvaia

Publications

Citations

H-Index

Page 1

	Year	Citations
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma Benjamin Bian, Daniele Fanale, Nelson Dusetti, OncoImmunology	2019	120
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer Gaetano Leto, Lorena Incorvaia, Giuseppe Badalamenti, Clinical & Experimental Metastasis UrologyBreast OncologyMedicinePathologyBreast Cancer	2006	115
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, The Lancet Oncology Endocrine OncologyBreast OncologyMedicinePharmacologyEndocrine-sensitive Breast Cancer	2018	86
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Lorena Incorvaia, Giuseppe Badalamenti, GiovamBattista Rini, PubMed	2007	82
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, OncoImmunology	2020	79
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives Stefania Gori, Massimo Barberis, Maria Angela Bella, Critical Reviews in Oncology/Hematology	2019	69
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients Francesco Passiglia, Antonio Galvano, Marta Castiglia, Therapeutic Advances in Medical Oncology	2019	64
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge Marco Bono, Daniele Fanale, Lorena Incorvaia, ESMO Open	2021	63
<i>BRCA1/2</i> pathogenic variants in triple-negative <i>versus</i> luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients Lorena Incorvaia, Daniele Fanale, Marco Bono, Therapeutic Advances in Medical Oncology	2020	61
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 Daniele Fanale, Lorena Incorvaia, Clarissa Filorizzo, Cancers	2020	54

Page 1